Definium Therapeutics Quarterly Balance Sheet
NASDAQ: DFTXHealth Care Medicinal Chemicals and Botanical Products USD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Definium Therapeutics financial position
As of Jun 30, 2026, Definium Therapeutics reported total assets of $1.11 billion, up 319.8% from a year earlier against total liabilities of $194.2 million. Shareholders' equity stood at $918.7 million, or 82.5% of assets. The company held $655.3 million in cash and equivalents against $36.5 million of debt, a net cash position of $618.8 million.
The current ratio (current assets divided by current liabilities) was 6.95, meaning short-term assets cover obligations due within a year. Debt-to-equity was 0.04.
Summary generated from market data by MetaCap's automated system. Methodology
Definium Therapeutics balance sheet (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | 655.27M | 262.52M | 257.84M | 19.96M | 33.39M | 82.85M | 273.74M | 295.28M | 243.13M | 252.33M | 99.70M | 117.70M |
| Short-Term Investments | 428.61M | 110.90M | 153.76M | 189.11M | 149.60M | 129.59M | 0 | — | — | — | — | — |
| Total Current Assets | 1.09B | 380.56M | 419.32M | 215.85M | 189.14M | 221.70M | 281.62M | 299.36M | 247.69M | 255.47M | 103.87M | 120.09M |
| Goodwill | 19.92M | 19.92M | 19.92M | 19.92M | 19.92M | 19.92M | 19.92M | 19.92M | 19.92M | 19.92M | 19.92M | 19.92M |
| Intangible Assets | — | — | — | — | — | — | 0 | — | — | — | 527.00K | 1.32M |
| Long-Term Investments | — | — | — | — | 54.86M | 33.10M | 0 | — | — | — | — | — |
| Total Assets | 1.11B | 401.29M | 440.10M | 236.92M | 265.09M | 275.32M | 302.15M | 319.77M | 268.14M | 275.53M | 124.54M | 141.55M |
| Accounts Payable | 6.96M | 7.13M | 5.35M | 8.11M | 4.22M | 2.27M | 2.01M | 2.15M | 2.94M | 7.59M | 4.14M | 7.69M |
| Total Current Liabilities | 157.20M | 81.11M | 66.70M | 65.42M | 37.96M | 30.48M | 38.85M | 33.27M | 41.85M | 65.27M | 32.25M | 31.15M |
| Long-Term Debt | 36.47M | 40.77M | 40.58M | 40.38M | 41.19M | 22.04M | 21.85M | 24.31M | 24.25M | 14.19M | 14.13M | 14.07M |
| Total Liabilities | 194.22M | 122.44M | 107.77M | 106.32M | 79.69M | 52.52M | 60.70M | 57.58M | 66.10M | 79.47M | 46.41M | 45.57M |
| Shareholders' Equity | 918.68M | 278.85M | 332.33M | 130.60M | 185.40M | 222.81M | 241.45M | 262.19M | 202.05M | 196.06M | 78.13M | 95.98M |
| Retained Earnings | -818.76M | -659.77M | -582.67M | -532.24M | -464.97M | -422.23M | -398.88M | -364.14M | -350.45M | -344.60M | -290.20M | -266.34M |
| Total Debt | 36.47M | 40.77M | 40.58M | 40.38M | 41.19M | 22.04M | 21.85M | 24.31M | 24.25M | 14.19M | 14.13M | 14.07M |
| Net Cash (Debt) | 1.05B | 332.65M | 371.01M | 168.69M | 141.80M | 190.41M | 251.89M | 270.97M | 218.88M | 238.14M | 85.58M | 103.63M |
| Shares Outstanding | 134.37M | 104.04M | 98.78M | 76.77M | 75.80M | 75.51M | 75.10M | 81.59M | 72.08M | 71.16M | 41.10M | 40.09M |
This table shows 12 quarterly periods of Definium Therapeutics's balance sheet, from Q2 2026 back to Q3 2023, across 16 line items including cash & equivalents, short-term investments, total current assets. Values in USD; B = billions, M = millions. Fiscal periods follow DFTX's reporting calendar. What is a balance sheet?